Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Identifieur interne : 004015 ( Main/Exploration ); précédent : 004014; suivant : 004016Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Auteurs : J. Gordon [États-Unis] ; U. Udeh ; K. Doobay ; C. Magro ; H. Wildman ; M. Davids ; J N Mersten ; W-T Huang ; S. Lyman ; M K Crow ; R F SpieraSource :
- Clinical and experimental rheumatology [ 0392-856X ]
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antirhumatismaux (usage thérapeutique), Association de médicaments, Benzamides (usage thérapeutique), Femelle, Glucocorticoïdes (usage thérapeutique), Humains, Hydroxychloroquine (usage thérapeutique), Inhibiteurs de la pompe à protons (usage thérapeutique), Inhibiteurs de protéines kinases (usage thérapeutique), Inhibiteurs des canaux calciques (usage thérapeutique), Mâle, Mésylate d'imatinib, Pipérazines (usage thérapeutique), Pneumopathies interstitielles (traitement médicamenteux), Pneumopathies interstitielles (étiologie), Prednisone (usage thérapeutique), Pyrimidines (usage thérapeutique), Résultat thérapeutique, Sclérodermie diffuse (), Sclérodermie diffuse (traitement médicamenteux), Tests de la fonction respiratoire.
- MESH :
- traitement médicamenteux : Pneumopathies interstitielles, Sclérodermie diffuse.
- usage thérapeutique : Antirhumatismaux, Benzamides, Glucocorticoïdes, Hydroxychloroquine, Inhibiteurs de la pompe à protons, Inhibiteurs de protéines kinases, Inhibiteurs des canaux calciques, Pipérazines, Prednisone, Pyrimidines.
- étiologie : Pneumopathies interstitielles.
- Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Mâle, Mésylate d'imatinib, Résultat thérapeutique, Sclérodermie diffuse, Tests de la fonction respiratoire.
English descriptors
- KwdEn :
- Adult, Antirheumatic Agents (therapeutic use), Benzamides (therapeutic use), Calcium Channel Blockers (therapeutic use), Drug Therapy, Combination, Female, Glucocorticoids (therapeutic use), Humans, Hydroxychloroquine (therapeutic use), Imatinib Mesylate, Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Male, Middle Aged, Piperazines (therapeutic use), Prednisone (therapeutic use), Protein Kinase Inhibitors (therapeutic use), Proton Pump Inhibitors (therapeutic use), Pyrimidines (therapeutic use), Respiratory Function Tests, Scleroderma, Diffuse (complications), Scleroderma, Diffuse (drug therapy), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antirheumatic Agents, Benzamides, Calcium Channel Blockers, Glucocorticoids, Hydroxychloroquine, Piperazines, Prednisone, Protein Kinase Inhibitors, Proton Pump Inhibitors, Pyrimidines.
- complications : Scleroderma, Diffuse.
- drug therapy : Lung Diseases, Interstitial, Scleroderma, Diffuse.
- etiology : Lung Diseases, Interstitial.
- Adult, Drug Therapy, Combination, Female, Humans, Imatinib Mesylate, Male, Middle Aged, Respiratory Function Tests, Treatment Outcome.
Abstract
We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).
PubMed: 25152211
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000284
- to stream PubMed, to step Curation: 000284
- to stream PubMed, to step Checkpoint: 000673
- to stream Ncbi, to step Merge: 000259
- to stream Ncbi, to step Curation: 000259
- to stream Ncbi, to step Checkpoint: 000259
- to stream Main, to step Merge: 004103
- to stream Main, to step Curation: 004015
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.</title><author><name sortKey="Gordon, J" sort="Gordon, J" uniqKey="Gordon J" first="J" last="Gordon">J. Gordon</name><affiliation wicri:level="2"><nlm:affiliation>Hospital for Special Surgery, New York, USA. gordonj@hss.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hospital for Special Surgery, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Udeh, U" sort="Udeh, U" uniqKey="Udeh U" first="U" last="Udeh">U. Udeh</name></author><author><name sortKey="Doobay, K" sort="Doobay, K" uniqKey="Doobay K" first="K" last="Doobay">K. Doobay</name></author><author><name sortKey="Magro, C" sort="Magro, C" uniqKey="Magro C" first="C" last="Magro">C. Magro</name></author><author><name sortKey="Wildman, H" sort="Wildman, H" uniqKey="Wildman H" first="H" last="Wildman">H. Wildman</name></author><author><name sortKey="Davids, M" sort="Davids, M" uniqKey="Davids M" first="M" last="Davids">M. Davids</name></author><author><name sortKey="Mersten, J N" sort="Mersten, J N" uniqKey="Mersten J" first="J N" last="Mersten">J N Mersten</name></author><author><name sortKey="Huang, W T" sort="Huang, W T" uniqKey="Huang W" first="W-T" last="Huang">W-T Huang</name></author><author><name sortKey="Lyman, S" sort="Lyman, S" uniqKey="Lyman S" first="S" last="Lyman">S. Lyman</name></author><author><name sortKey="Crow, M K" sort="Crow, M K" uniqKey="Crow M" first="M K" last="Crow">M K Crow</name></author><author><name sortKey="Spiera, R F" sort="Spiera, R F" uniqKey="Spiera R" first="R F" last="Spiera">R F Spiera</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2014 Nov-Dec</MedlineDate></PubDate></date><idno type="RBID">pubmed:25152211</idno><idno type="pmid">25152211</idno><idno type="wicri:Area/PubMed/Corpus">000284</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000284</idno><idno type="wicri:Area/PubMed/Curation">000284</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000284</idno><idno type="wicri:Area/PubMed/Checkpoint">000673</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000673</idno><idno type="wicri:Area/Ncbi/Merge">000259</idno><idno type="wicri:Area/Ncbi/Curation">000259</idno><idno type="wicri:Area/Ncbi/Checkpoint">000259</idno><idno type="wicri:doubleKey">0392-856X::Gordon J:imatinib:mesylate:gleevec</idno><idno type="wicri:Area/Main/Merge">004103</idno><idno type="wicri:Area/Main/Curation">004015</idno><idno type="wicri:Area/Main/Exploration">004015</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.</title><author><name sortKey="Gordon, J" sort="Gordon, J" uniqKey="Gordon J" first="J" last="Gordon">J. Gordon</name><affiliation wicri:level="2"><nlm:affiliation>Hospital for Special Surgery, New York, USA. gordonj@hss.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hospital for Special Surgery, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Udeh, U" sort="Udeh, U" uniqKey="Udeh U" first="U" last="Udeh">U. Udeh</name></author><author><name sortKey="Doobay, K" sort="Doobay, K" uniqKey="Doobay K" first="K" last="Doobay">K. Doobay</name></author><author><name sortKey="Magro, C" sort="Magro, C" uniqKey="Magro C" first="C" last="Magro">C. Magro</name></author><author><name sortKey="Wildman, H" sort="Wildman, H" uniqKey="Wildman H" first="H" last="Wildman">H. Wildman</name></author><author><name sortKey="Davids, M" sort="Davids, M" uniqKey="Davids M" first="M" last="Davids">M. Davids</name></author><author><name sortKey="Mersten, J N" sort="Mersten, J N" uniqKey="Mersten J" first="J N" last="Mersten">J N Mersten</name></author><author><name sortKey="Huang, W T" sort="Huang, W T" uniqKey="Huang W" first="W-T" last="Huang">W-T Huang</name></author><author><name sortKey="Lyman, S" sort="Lyman, S" uniqKey="Lyman S" first="S" last="Lyman">S. Lyman</name></author><author><name sortKey="Crow, M K" sort="Crow, M K" uniqKey="Crow M" first="M K" last="Crow">M K Crow</name></author><author><name sortKey="Spiera, R F" sort="Spiera, R F" uniqKey="Spiera R" first="R F" last="Spiera">R F Spiera</name></author></analytic><series><title level="j">Clinical and experimental rheumatology</title><idno type="ISSN">0392-856X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antirheumatic Agents (therapeutic use)</term><term>Benzamides (therapeutic use)</term><term>Calcium Channel Blockers (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Imatinib Mesylate</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Lung Diseases, Interstitial (etiology)</term><term>Male</term><term>Middle Aged</term><term>Piperazines (therapeutic use)</term><term>Prednisone (therapeutic use)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Proton Pump Inhibitors (therapeutic use)</term><term>Pyrimidines (therapeutic use)</term><term>Respiratory Function Tests</term><term>Scleroderma, Diffuse (complications)</term><term>Scleroderma, Diffuse (drug therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Association de médicaments</term><term>Benzamides (usage thérapeutique)</term><term>Femelle</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Inhibiteurs de la pompe à protons (usage thérapeutique)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Inhibiteurs des canaux calciques (usage thérapeutique)</term><term>Mâle</term><term>Mésylate d'imatinib</term><term>Pipérazines (usage thérapeutique)</term><term>Pneumopathies interstitielles (traitement médicamenteux)</term><term>Pneumopathies interstitielles (étiologie)</term><term>Prednisone (usage thérapeutique)</term><term>Pyrimidines (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sclérodermie diffuse ()</term><term>Sclérodermie diffuse (traitement médicamenteux)</term><term>Tests de la fonction respiratoire</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Benzamides</term><term>Calcium Channel Blockers</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Piperazines</term><term>Prednisone</term><term>Protein Kinase Inhibitors</term><term>Proton Pump Inhibitors</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Scleroderma, Diffuse</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases, Interstitial</term><term>Scleroderma, Diffuse</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Pneumopathies interstitielles</term><term>Sclérodermie diffuse</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Benzamides</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term><term>Inhibiteurs de la pompe à protons</term><term>Inhibiteurs de protéines kinases</term><term>Inhibiteurs des canaux calciques</term><term>Pipérazines</term><term>Prednisone</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Imatinib Mesylate</term><term>Male</term><term>Middle Aged</term><term>Respiratory Function Tests</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Mésylate d'imatinib</term><term>Résultat thérapeutique</term><term>Sclérodermie diffuse</term><term>Tests de la fonction respiratoire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Crow, M K" sort="Crow, M K" uniqKey="Crow M" first="M K" last="Crow">M K Crow</name><name sortKey="Davids, M" sort="Davids, M" uniqKey="Davids M" first="M" last="Davids">M. Davids</name><name sortKey="Doobay, K" sort="Doobay, K" uniqKey="Doobay K" first="K" last="Doobay">K. Doobay</name><name sortKey="Huang, W T" sort="Huang, W T" uniqKey="Huang W" first="W-T" last="Huang">W-T Huang</name><name sortKey="Lyman, S" sort="Lyman, S" uniqKey="Lyman S" first="S" last="Lyman">S. Lyman</name><name sortKey="Magro, C" sort="Magro, C" uniqKey="Magro C" first="C" last="Magro">C. Magro</name><name sortKey="Mersten, J N" sort="Mersten, J N" uniqKey="Mersten J" first="J N" last="Mersten">J N Mersten</name><name sortKey="Spiera, R F" sort="Spiera, R F" uniqKey="Spiera R" first="R F" last="Spiera">R F Spiera</name><name sortKey="Udeh, U" sort="Udeh, U" uniqKey="Udeh U" first="U" last="Udeh">U. Udeh</name><name sortKey="Wildman, H" sort="Wildman, H" uniqKey="Wildman H" first="H" last="Wildman">H. Wildman</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Gordon, J" sort="Gordon, J" uniqKey="Gordon J" first="J" last="Gordon">J. Gordon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004015 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004015 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25152211
|texte= Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25152211" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |